Cargando…

Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma

This report summarizes the proceedings of the 4th European Bone Sarcoma Networking Meeting, held in London, England, on 21 June 2017. The meeting brought together scientific and clinical researchers and representatives from sarcoma charities from 19 countries representing five networks across Europe...

Descripción completa

Detalles Bibliográficos
Autores principales: Strauss, Sandra J., Anninga, Jakob, Baglio, Rubina, Baumhoer, Daniel, Behjati, Sam, Bielack, Stefan, Boye, Kjetil, Broto, Javier M., Cleton-Jansen, Anne-Marie, Degasperi, Andrea, Evans, Abigail, Fagioli, Franca, Fiocco, Marta, Gaspar, Nathalie, Heymann, Dominique, Hindi, Nadia, Lancia, Carlo, Myklebost, Ola, Nathrath, Michaela, Redini, Francoise, Scotlandi, Katia, Tirtei, Elisa, Vanden Eynden, Michel, Whelan, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094460/
http://dx.doi.org/10.1186/s13569-018-0103-0
Descripción
Sumario:This report summarizes the proceedings of the 4th European Bone Sarcoma Networking Meeting, held in London, England, on 21 June 2017. The meeting brought together scientific and clinical researchers and representatives from sarcoma charities from 19 countries representing five networks across Europe, to present and discuss new developments on bone sarcoma. In view of the challenges is poses, the meeting focussed primarily on osteosarcoma with presentations on developments in our understanding of osteosarcoma genetics and immunology as well as results from preclinical investigations and discussion of recent and ongoing clinical trials. These include studies examining the efficacy of multi-targeted tyrosine kinase inhibitors and checkpoint inhibitors, as well as those with molecular profiling to stratify patients for specific therapies. Discussion was centred on generation of new hypotheses for collaborative biological and clinical investigations, the ultimate goal being to improve therapy and outcome in patients with bone sarcomas.